Panacea Index Logo

Command Palette

Search for a command to run...

A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter?

PloS one
January 1, 2018
Amie L Hiller et al. (6 authors)
Journal ArticleRandomized Controlled TrialResearch Support, U.S. Gov't, Non-P.H.S.Human StudyClinical
Study Details

Study Goal

The researchers aimed to evaluate the safety and effects of high-dose vitamin D supplementation on balance and other motor/non-motor features in Parkinson's disease patients, with all participants receiving 1000 mg calcium daily as a co-intervention.

Results Summary

The study did not report specific outcomes related to calcium; it focused on vitamin D's effects, noting no serious adverse events and a post hoc improvement in balance for younger participants.

Population

Persons with Parkinson's disease (ages 52-86).

Effective Dosage

1000 mg calcium once daily.

Duration

16 weeks.

Interactions

None mentioned.

Extracted Claims (8)
InterventionDirectionEndpointPopulationDosageImpactClaim #
high dose vitamin D supplementation (10,000 IU/day)
increase
serum concentrations of vitamin D (25-OH)
persons with Parkinson's disease (PD)
30.2 ng/ml to 61.1 ng/ml
resulted in a rise
#1
high dose vitamin D supplementation (10,000 IU/day)
no change
safety
persons with Parkinson's disease (PD)
no serious adverse events
was well tolerated
#2
high dose vitamin D supplementation (10,000 IU/day)
no change
balance as measured by the Sensory Organization Test
persons with Parkinson's disease (PD)
p = 0.43
did not significantly improve
#3
high dose vitamin D supplementation (10,000 IU/day)
increase
Sensory Organization Test (SOT)
younger (ages 52-66) participants with PD
10.6 points
found a significant improvement
#4
high dose vitamin D supplementation (10,000 IU/day)
no change
safety
persons with PD
-
appears safe
#5
high dose vitamin D supplementation (10,000 IU/day)
no change
balance as measured with the Sensory Organization Test
pilot study population with PD
-
did not significantly improve
#6
vitamin D
increase
balance
younger population with PD
-
may have potential for improving
#7
mega doses and even moderate doses (as low as 4000IU a day) of vitamin D
increase
falls
older populations
-
may increase
#8
Abstract

OBJECTIVES: To explore if short term, high dose vitamin D supplementation is safe and improves balance in persons with Parkinson's disease (PD). METHODS: A pilot randomized, double-blind intervention trial to measure the effects of 16 weeks of high dose vitamin D (10,000 IU/day) on balance as well as other motor and non-motor features of PD. We measured balance, gait, strength, falls, cognition, mood, PD severity, and quality of life before and after 16 weeks of high dose vitamin D supplementation or placebo. All participants also received 1000 mg calcium once daily. RESULTS: Fifty-one randomized participants completed sixteen weeks of high dose vitamin D supplementation or placebo. The intervention resulted in a rise in serum concentrations of vitamin D (25-OH) (30.2 ng/ml to 61.1 ng/ml) and was well tolerated with no serious adverse events. Serum vitamin D (25-OH) levels rose steadily and did not suggest a leveling off at the end of the 16 weeks. There was not an improvement in the primary endpoint, balance as measured by the Sensory Organization Test (p = 0.43). A post hoc analysis examining treatment effects in younger (ages 52-66) versus older (ages 67-86) participants found a significant improvement in the SOT of 10.6 points in the younger half of the cohort (p = 0.012). CONCLUSIONS: Short term, high dose vitamin D supplementation appears safe in persons with PD, but did not significantly improve balance as measured with the Sensory Organization Test in this pilot study population. A post hoc analysis suggests that vitamin D may have potential for improving balance in a younger population with PD. High dose vitamin D supplementation in PD needs further study especially in light of new research suggesting that mega doses and even moderate doses (as low as 4000IU a day) may increase falls in an older populations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01119131.

Medical Subject Headings (MeSH)
Age FactorsAgedAged, 80 and overCalciumDouble-Blind MethodFemaleHumansMaleMiddle AgedParkinson DiseaseTreatment OutcomeVitamin D
Study Links
Quality Scores
SafetyNot Assessed
Quality75/10
Citation Metrics
Total Citations49
Citations/Year7.0
Relative Citation Ratio2.63
NIH Percentile82%
Research Impact Scores
APT Score0.50
Weight Score2.18
Normalized Score0.55
Related Supplements